Zyme is $6.50 and just got a cash buyout offer for $10.50. It’s shows to have a short interest of 15% and a float of 20 million on roughly 58 million shares.
Here’s some internet info.
Cash:
In its last quarterly report, Zymeworks reported that it had $307.8 million in cash resources — with enough on the budget to get it going until late 2022
Also:
Zymeworks Inc (US:ZYME) has 181 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 46,775,231 shares. Largest shareholders include Perceptive Advisors Llc, Fmr Llc, Wellington Management Group Llp, Eventide Asset Management, Llc, ETAHX – Eventide Healthcare & Life Sciences Fund Class A Shares, Bank Of America Corp /de/, Goldman Sachs Group Inc, Credit Suisse Ag/, Morgan Stanley, and Price T Rowe Associates Inc /md/.
Zymeworks Inc (NYSE:ZYME) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.
The share price as of April 27, 2022 is 4.86 / share. Previously, on April 28, 2021, the share price was 31.84 / share. This represents a decline of 84.74% over that period.
What do you think? Seems like an interesting situation if you ask me.
Leave a Reply